GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (STU:9IP1) » Definitions » Unearned Premiums

Rocket Pharmaceuticals (STU:9IP1) Unearned Premiums


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Unearned Premiums?

Unearned Premiums only applies to insurance companies.


Rocket Pharmaceuticals Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.